Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment

@article{Clark1997InductionOM,
  title={Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment},
  author={Joseph I Clark and R Katherine Alpaugh and Margaret von Mehren and Josephine Schultz and Julie R. Gralow and Martin A. Cheever and David B. Ring and Louis M. Weiner},
  journal={Cancer Immunology, Immunotherapy},
  year={1997},
  volume={44},
  pages={265-272}
}
 The bispecific monoclonal antibody (bsmAb) 2B1, targeting the extracellular domain of c-erbB-2, the protein product of the HER-2/neu proto-oncogene, and FcγRIII (CD16), expressed by human natural killer cells, neutrophils and differentiated monocytes, mediates the specific cytotoxic activity of these effector cells to tumor cells. A group of 24 patients with c-erbB-2-overexpressing tumors were treated with intravenously administered 2B1 in a phase I clinical trial and followed after treatment… CONTINUE READING